However, there exist heartening outcomes of phase II of the clinical trials of some cancer vaccines, namely Canvaxin and GM-CSF gene modified tumor vaccine (GVAX) in curing melanoma and PCa, respectively which stimulate antigen cross-presentation and variety, culminating in the protective immunity against cancer (125–128). This evidence concerns the gene CSF2 and cancer.